Novartis announced the acquisition of Tourmaline Bio for $1.4 billion, obtaining exclusive rights to an anti-inflammatory heart medication nearing Phase 3 trials. The deal is set to bolster Novartis' cardiovascular portfolio with a drug that demonstrated promising mid-stage results earlier this year. Tourmaline's lead candidate joins Novartis' efforts to innovate treatments for heart disease, addressing a critical global health burden. This strategic move underlines Big Pharma's continued investment in cardiovascular drug development.